Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

<p>Treemap of most common drug mechanisms for patients treated in biomarker-matched studies.</p>

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Roberto Carmagnani Pestana (15294422) (author)
Άλλοι συγγραφείς:	Justin T. Moyers (15047706) (author), Jason Roszik (15017091) (author), Shiraj Sen (15294425) (author), David S. Hong (15019257) (author), Aung Naing (15023555) (author), Cynthia E. Herzog (15012524) (author), Siqing Fu (15047712) (author), Sarina A. Piha-Paul (15294428) (author), Jordi Rodon (15047721) (author), Timothy A. Yap (15028749) (author), Daniel D. Karp (15294431) (author), Apostolia M. Tsimberidou (15294434) (author), Shubham Pant (15122815) (author), Maria A. Zarzour (15294437) (author), Ravin Ratan (15044195) (author), Vinod Ravi (15047730) (author), Robert S. Benjamin (15012521) (author), Alexander J. Lazar (14963562) (author), Wei-Lien Wang (15294440) (author), Najat Daw (15294443) (author), Jonathan B. Gill (15086581) (author), Douglas J. Harrison (15294446) (author), Valerae O. Lewis (15294449) (author), Christina L. Roland (15294452) (author), Shreyaskumar R. Patel (15062448) (author), J. Andrew Livingston (15294455) (author), Neeta Somaiah (14963553) (author), Joseph A. Ludwig (15016911) (author), Anthony P. Conley (15294458) (author), Nelson Hamerschlak (15294461) (author), Richard Gorlick (15019631) (author), Funda Meric-Bernstam (10258780) (author), Vivek Subbiah (8737068) (author)
Έκδοση:	2025
Θέματα:	Cancer Therapeutic Research and Development Clinical Research and Trials Biological Agents & Therapies Drug Targets Precision Medicine Sarcomas
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια

SPIRIT schedule of enrollment, interventions, and assessment.
ανά: Kim Christin Honselmann (21176936)
Έκδοση: (2025)

Participant timeline: Schedule of enrollment, interventions, and assessments.
ανά: Pierre Angelvy (22683450)
Έκδοση: (2025)

A table showing the clinical participants who were enrolled in a further or higher education course and their research activity and self-declared involvement.
ανά: Zoe Edwards (3823528)
Έκδοση: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
ανά: James S. Wilmott (15008931)
Έκδοση: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
ανά: James S. Wilmott (15008931)
Έκδοση: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
ανά: Iris van 't Erve (15054503)
Έκδοση: (2025)

Serum neuregulin -1 (NRG-1) is a potential biomarker for early diagnosis and prediction in refractory schizophrenia
ανά: Ming Shu (22683656)
Έκδοση: (2025)

Figure 1 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
ανά: Marianna Carrabotta (8193039)
Έκδοση: (2025)

Figure 2 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
ανά: Marianna Carrabotta (8193039)
Έκδοση: (2025)

Figure 3 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
ανά: Marianna Carrabotta (8193039)
Έκδοση: (2025)

Figure 4 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
ανά: Marianna Carrabotta (8193039)
Έκδοση: (2025)

Figure 5 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
ανά: Marianna Carrabotta (8193039)
Έκδοση: (2025)

Table 1 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
ανά: Marianna Carrabotta (8193039)
Έκδοση: (2025)

Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
ανά: Sebastian Johannes Schober (14971891)
Έκδοση: (2025)

Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
ανά: Sebastian Johannes Schober (14971891)
Έκδοση: (2025)

Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
ανά: Sebastian Johannes Schober (14971891)
Έκδοση: (2025)

Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
ανά: Sebastian Johannes Schober (14971891)
Έκδοση: (2025)

Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
ανά: Sebastian Johannes Schober (14971891)
Έκδοση: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
ανά: Milana A. Bergamino (15038015)
Έκδοση: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
ανά: Milana A. Bergamino (15038015)
Έκδοση: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
ανά: Milana A. Bergamino (15038015)
Έκδοση: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
ανά: Milana A. Bergamino (15038015)
Έκδοση: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
ανά: Milana A. Bergamino (15038015)
Έκδοση: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
ανά: Milana A. Bergamino (15038015)
Έκδοση: (2025)

Supplementary Table 1 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
ανά: David Olayinka Kamson (16617218)
Έκδοση: (2025)

Supplementary Table 2 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
ανά: David Olayinka Kamson (16617218)
Έκδοση: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
ανά: Nigel Bundred (15046233)
Έκδοση: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
ανά: Nigel Bundred (15046233)
Έκδοση: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
ανά: Nigel Bundred (15046233)
Έκδοση: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
ανά: Nigel Bundred (15046233)
Έκδοση: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
ανά: Nigel Bundred (15046233)
Έκδοση: (2025)

Table S1. Isometric handgrip force-matched participant demographics and LV morphology.
ανά: Corey Tomczak (22648301)
Έκδοση: (2025)

Data_Sheet_1_Benchmarking quantum annealing with maximum cardinality matching problems.PDF
ανά: Daniel Vert (18769933)
Έκδοση: (2025)

<b>Figure S1.</b><b> Cardiac MRI LV volume responses to EX and MMA in</b><b> </b><b>i</b><b>sometric handgrip force-matched-matched males and females</b>
ανά: Corey Tomczak (22648301)
Έκδοση: (2025)

Supplementary Figure S1 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
ανά: Benjamin K. Wilke (15055112)
Έκδοση: (2025)

Supplementary Figure S2 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
ανά: Benjamin K. Wilke (15055112)
Έκδοση: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
ανά: Tom Wei-Wu Chen (15053003)
Έκδοση: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
ανά: Tom Wei-Wu Chen (15053003)
Έκδοση: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
ανά: Tom Wei-Wu Chen (15053003)
Έκδοση: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
ανά: Tom Wei-Wu Chen (15053003)
Έκδοση: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ijcp20m4bughmh5vtajnve0iob